The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer

Table 2 Survival analysis of ovarian cancer patients including coexpression of PELP1/ERbeta in the test set (A) and validation set (B)

	Disease-free survival			Overall survival
	Univariate ¹	Multivariate ²		Univariate ¹	Multivariate ²
	P-Value	P-Value	HR (95%CI)	P-Value	P-Value	HR (95%CI)
Patients’ age	0.9	0.09	2.1 (0.9-4.9)	0.9	0.4	1.4 (0.6-3.0)
Histological type (serous vs. non-serous)	0.6	0.6	0.8 (0.4-1.8)	0.4	0.9	0.9 (0.5-2.2)
FIGO stage (I vs. II vs. III vs. IV)	<0.001	<0.001	4.4 (1.9-10.1)	<0.001	0.007	3.2 (1.4-7.6)
Residual tumor(no vs. yes)	<0.001	0.9	0.9 (0.4-2.6)	<0.001	0.4	1.6 (0.6-4.3)
ERalpha (negative vs. positive)	0.8	-	-	0.9	-	-
ERbeta (negative vs. positive)	0.3	-	-	0.2	-	-
PELP1 (negative vs. positive)	0.004	-	-	0.04	-	-
PELP1/ERbeta (ERbeta+/PELP1+ vs. others)	0.03	0.004	0.3 (0.1-0.7)	0.02	0.005	0.3 (0.1-0.7)
	Disease-free survival			Overall survival
	Univariate ¹	Multivariate ²		Univariate ¹	Multivariate ²
	P-Value	P-Value	HR (95%CI)	P-Value	P-Value	HR (95%CI)
Patients’ age	0.09	0.4	1.3 (0.7-2.2)	0.005	0.04	2.4 (1.1-5.3)
FIGO stage (I vs. II vs. III vs. IV)	0.001	0.02	1.8 (1.1-3.0)	0.001	0.005	2.5 (1.3-4.7)
Residual tumor (no vs. yes)	0.003	0.1	1.6 (0.9-1.8)	0.02	0.3	1.4 (0.7-2.7)
ERalpha (negative vs. positive)	0.2	-	-	0.6	-	-
ERbeta (negative vs. positive)	0.7	-	-	0.2	-	-
PELP1 (negative vs. positive)	0.8	-	-	0.9	-	-
PELP1/ERbeta (ERbeta+/PELP1+ vs. others)	0.6	0.3	0.7 (0.4-1.3)	0.9	0.3	0.7 (0.3-1.4)

¹Log rank test; ²multivariate Cox-regression analysis, HR=Hazard Ratio, 95%CI= 95% Confidence Interval.

ISSN: 1471-2407